Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 1, 2001, Pages 2-6

  Setnikar, I ^a   Schmid, K ^a   Rovati, L C ^a   Vens Cappell, B ^a   Mazur, D ^a   Kozak, I ^a  

^a Rotta Research Laboratorium   (Italy)

Author keywords

CAS 8067 24 1; Dihydroergotoxine, bioavailability, pharmacokinetics; Ergoloid mesylates; Orphol forte; Orphol spezial

Indexed keywords

DIHYDROERGOCORNINE; DIHYDROERGOCRISTINE; DIHYDROERGOCRYPTINE; DIHYDROERGOTOXINE; ERGOT ALKALOID; MESYLIC ACID DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RADIOIMMUNOASSAY; TABLET; VERTIGO;

EID: 0035137804     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299995     Document Type: Article

References (17)

1. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man
2. The absolute systemic availability of a new oral formulation of Co-Derocrine in healthy subjects
3. Adverse drug reactions: Definitions, diagnosis, and management
4. Ergoloid mesylates
5. A distribution-free procedure for the statistical analysis of bioequivalence studies
6. Renal excretion of dihydrogenated alkaloids of ergotoxine in man
7. Spezifität und Präzision einer radioimmunologischen Bestimmung von Dihydroergotoxin im Plasma
8. Interaction of ergot alkaloids and their combination (codergocrine) with α-adrenoceptors in the CNS
9. Reliability of symptom reports by healthy volunteers treated with placebo over several time periods
10. Generic substitution: Does interchangeability mean equality of all functional relevant attributes?
11. Uniformity of content of single dose preparations
12. Co-dergoline mesylate. A review of its pharmacodynamic and pharmacokientic properties and therapeutic use in age related cognitive decline
13. Absorption kinetics of dihydroergotoxine following oral formulation of Co-Derocrine in healthy subjects